Quotient Stock Forecast, Price & News

Quotient (NASDAQ:QTNT) Frequently Asked Questions

Is Quotient a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Quotient stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QTNT, but not buy additional shares or sell existing shares.
View analyst ratings for Quotient or view top-rated stocks.

How has Quotient's stock price been impacted by COVID-19 (Coronavirus)?

Quotient's stock was trading at $4.64 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QTNT shares have decreased by 53.9% and is now trading at $2.14.
View which stocks have been most impacted by COVID-19.

When is Quotient's next earnings date?

Quotient is scheduled to release its next quarterly earnings announcement on Monday, February 7th 2022.
View our earnings forecast for Quotient.

How were Quotient's earnings last quarter?

Quotient Limited (NASDAQ:QTNT) issued its quarterly earnings data on Monday, November, 15th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.28). The firm earned $9.47 million during the quarter, compared to analysts' expectations of $8.30 million.
View Quotient's earnings history.

What price target have analysts set for QTNT?

1 Wall Street analysts have issued 1 year price objectives for Quotient's shares. Their forecasts range from $3.50 to $3.50. On average, they anticipate Quotient's stock price to reach $3.50 in the next twelve months. This suggests a possible upside of 63.6% from the stock's current price.
View analysts' price targets for Quotient or view top-rated stocks among Wall Street analysts.

Who are Quotient's key executives?

Quotient's management team includes the following people:

• Manuel O. Méndez Muñiz, Chief Executive Officer & Director
• Ali J. Kiboro, Chief Financial Officer
• Christine Ginocchio, Chief Scientific & Medical Officer
• Mohammad El Khoury, Chief Commercial Officer
• Christian Albrich, Chief People Officer

Who are some of Quotient's key competitors?

Some companies that are related to Quotient include Alpha Teknova (TKNO), Lucira Health (LHDX), MyMD Pharmaceuticals (MYMD), OncoCyte (OCX), VolitionRx (VNRX), Aspira Women's Health (AWH), Nymox Pharmaceutical (NYMX), Achieve Life Sciences (ACHV), ImmuCell (ICCC), Biomerica (BMRA), Navidea Biopharmaceuticals (NAVB), ARCA biopharma (ABIO), Trinity Biotech (TRIB), StageZero Life Sciences (SZLSF) and StageZero Life Sciences (GNWSF).
View all of QTNT's competitors.

What other stocks do shareholders of Quotient own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Verastem (VSTM), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX), Novavax (NVAX), Ocular Therapeutix (OCUL) and Sorrento Therapeutics (SRNE).

What is Quotient's stock symbol?

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Who are Quotient's major shareholders?

Quotient's stock is owned by a number of institutional and retail investors. Top institutional investors include Cutler Group LP (0.00%) and First Midwest Bank Trust Division (0.05%). Company insiders that own Quotient stock include Edward Farrell, Jeremy Stackawitz, Khoury Mohammad El, Perceptive Advisors Llc, Peter Buhler and Prondzynski Heino Von.
View institutional ownership trends for Quotient.

Which institutional investors are selling Quotient stock?

QTNT stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division.
View insider buying and selling activity for Quotient or view top insider-selling stocks.

Which institutional investors are buying Quotient stock?

QTNT stock was purchased by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have bought Quotient stock in the last two years include Khoury Mohammad El, Perceptive Advisors Llc, Peter Buhler, and Prondzynski Heino Von.
View insider buying and selling activity for Quotient or or view top insider-buying stocks.

How do I buy shares of Quotient?

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quotient's stock price today?

One share of QTNT stock can currently be purchased for approximately $2.14.

How much money does Quotient make?

Quotient has a market capitalization of $218.91 million and generates $43.38 million in revenue each year. The company earns $-111.03 million in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Quotient have?

Quotient employs 435 workers across the globe.

What is Quotient's official website?

The official website for Quotient is www.quotientbd.com.

Where are Quotient's headquarters?

Quotient is headquartered at B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262.

How can I contact Quotient?

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The company can be reached via phone at (122) 716-9800 or via email at [email protected].